1. Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy
- Author
-
Ke Du, Qiuyu Xia, Jian Sun, and Fude Feng
- Subjects
Materials science ,Light ,Cell Survival ,Polymers ,Surface Properties ,Conjugated system ,Micelle ,chemistry.chemical_compound ,Drug Delivery Systems ,Cell Line, Tumor ,Glioma ,Temozolomide ,medicine ,Humans ,Prodrugs ,General Materials Science ,Particle Size ,Triazene ,Antineoplastic Agents, Alkylating ,Cell Proliferation ,chemistry.chemical_classification ,Molecular Structure ,Glutathione ,Prodrug ,medicine.disease ,Drug Liberation ,chemistry ,Cancer research ,Thiol ,Drug Screening Assays, Antitumor ,Glioblastoma ,medicine.drug - Abstract
Temozolomide (TMZ) is a prodrug of 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide (MTIC, short-lived) and used as a first-line therapy drug for glioblastoma multiforme (GBM). However, little progress has been made in regulating the kinetics of TMZ to MTIC degradation to improve the therapeutic effect, particularly in the case of TMZ-resistant GBM. In this work, we introduced a strategy to cage MTIC by N-acylation of the triazene moiety to boost the MTIC stability, designed a diblock copolymer-based MTIC prodrug installed with a disulfide linkage, and achieved self-assembled polymer micelles without the concern of MTIC leakage under physiological conditions. Polymer micelles could be induced to disassemble by stimuli factors such as glutathione (GSH) and visible light irradiation through thiol/sulfide exchange and homolytic sulfide scission mechanisms, which contributed to MTIC release in GSH-dependent and GSH-independent pathways. The in vitro results demonstrated that microenvironment-responsive polymeric micelles benefited the suppression of both TMZ-sensitive and TMZ-resistant GBM cells. The chemistry of polymer-MTIC prodrug provided a new option for TMZ-based glioma treatment.
- Published
- 2021